Explore the latest news and coverage about Bariendo
Dr. Thompson was quoted by Investor's Business Daily advocating for a more thoughtful approach to using continuous glucose monitors.
The article highlights an initial quality-of-life drop in surgical patients in the first week post-op and a 20% non-adherence rate for semaglutide users.
This study shows ESG is more cost-effective than Semaglutide for class II obesity due to its higher effectiveness and lower costs.
Lauren emphasizes balance, moderation, and adding nutritious foods to reduce inflammation and manage weight.
Dr. Christopher Thompson examines the benefits, costs, and risks of different weight-loss treatments.
Dr. Pichamol Jirapinyo highlighted the exclusion of obese individuals from clinical trials and its implications.
Dr. Jirapinyo advises only taking GLP-1 medications under a doctor's supervision and cautions against non-FDA-approved versions.
Dr. Thompson advocates treating obesity as a disease using GLP-1 medications, ESG, and lifestyle changes.
Dr. Thompson explains weight loss plateaus occur when weight remains unchanged for a month despite consistent diet and exercise.
Dr. Thompson highlights that tirzepatide lowers normal blood pressure with weight loss, not hypertension.